Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases

Funding:
Arda Therapeutics has raised $43 million in a Series A funding round led by Andreessen Horowitz (a16z) with participation from Eli Lilly and other investors.

Focus:
The funding will be used to develop antibody-drug conjugates (ADCs) specifically targeting fibrotic diseases by eliminating pathogenic cells driving disease progression.

Platform:
Arda leverages a proprietary platform that integrates single-cell data with machine learning to identify and eliminate disease-causing cell populations.

Expansion:
This funding represents a significant step toward applying ADC technology into the fibrosis space, beyond its current applications in oncology.

Partnership:
The investment by Eli Lilly underscores the strategic expansion into immunology and inflammation-focused treatments, aligning with Lilly's broader research interests.